Evidence map›Paper›PMID 37439177›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2023

[Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms].

D Luo, J Luo, H Liang, Z He, H Chen, Z Wen, Q Wang, X Zhou, X Liu, N Xu

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

D LuoDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J LuoDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
H LiangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Z HeDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
H ChenDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Z WenDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Q WangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
X ZhouDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
X LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
N XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Nanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the clinical efficacy and adverse reactions of peginterferon-α2b for treatment of chronic myeloproliferative neoplasms (MPN).

methodsWe retrospectively analyzed the data of 107 patients with MPN, including 95 with essential thrombocythemia (ET) and 12 with polycythemia vera (PV), who all received peginterferon-α2b treatment for at least 12 months. The clnical and follow-up data of the patients were analyzed to evaluate the efficacy and adverse reactions of the treatment.

resultsAfter receiving peginterferon- α2b treatment, both ET and PV patients achieved high hematological remission rates, and the total remission rates did not differ significantly between the two groups (86%

conclusionFor patients with chronic myelodysplasia, peginterferon-α2b treatment can achieve a high peripheral blood cell remission rate and maintain a long-term stable state with good effect in relieving symptoms such as splenomegaly. Peginterferon- α2b treatment caused only mild adverse reactions, which can be tolerated by most of the patients.

Indexed as

Interferon alpha-2NeoplasmsAllelesHumansInterferon-alphaMyeloproliferative DisordersPolyethylene GlycolsRecombinant ProteinsRetrospective StudiesSpleenInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant Proteinsessential thrombocythemiamyeloproliferative neoplasmspeginterferon-α2bpolycythemia vera

Identifiers

PMID37439177
PMCPMC10339308
OpenAlexW4384120630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.